Newsroom: Archives

January 13, 2021

Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics

 

December 23, 2020

A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers

 

October 6, 2020

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics

 

November 5, 2019

A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics